Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study

J Brown, D Buckley, A Coulthard, A K Dixon, J M Dixon, D F Easton, R A Eeles, D G R Evans, F G Gilbert, M Graves, C Hayes, J P R Jenkins, A P Jones, S F Keevil, M O Leach, G P Liney, S M Moss, A R Padhani, G J M Parker, L J Pointon & 7 others B A J Ponder, T W Redpath, J P Sloane, L W Turnbull, L G Walker, R M L Warren, UK MRI Breast Screening Study Advisory Group

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.

Original languageEnglish
Pages (from-to)765-776
Number of pages12
JournalMagnetic Resonance Imaging
Volume18
Publication statusPublished - 2000

Keywords

  • breast cancer
  • genetic predisposition
  • screening
  • contrast agent
  • mammography
  • CONTRAST-ENHANCED MRI
  • GD-DTPA ENHANCEMENT
  • PHARMACOKINETIC ANALYSIS
  • PATHOLOGICAL CORRELATION
  • FAMILY HISTORY
  • LESIONS
  • DIAGNOSIS
  • DIFFERENTIATION
  • EXPERIENCE
  • CARCINOMA

Cite this

Brown, J., Buckley, D., Coulthard, A., Dixon, A. K., Dixon, J. M., Easton, D. F., ... UK MRI Breast Screening Study Advisory Group (2000). Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magnetic Resonance Imaging, 18, 765-776.

Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. / Brown, J ; Buckley, D ; Coulthard, A ; Dixon, A K ; Dixon, J M ; Easton, D F ; Eeles, R A ; Evans, D G R ; Gilbert, F G ; Graves, M ; Hayes, C ; Jenkins, J P R ; Jones, A P ; Keevil, S F ; Leach, M O ; Liney, G P ; Moss, S M ; Padhani, A R ; Parker, G J M ; Pointon, L J ; Ponder, B A J ; Redpath, T W ; Sloane, J P ; Turnbull, L W ; Walker, L G ; Warren, R M L ; UK MRI Breast Screening Study Advisory Group.

In: Magnetic Resonance Imaging, Vol. 18, 2000, p. 765-776.

Research output: Contribution to journalArticle

Brown, J, Buckley, D, Coulthard, A, Dixon, AK, Dixon, JM, Easton, DF, Eeles, RA, Evans, DGR, Gilbert, FG, Graves, M, Hayes, C, Jenkins, JPR, Jones, AP, Keevil, SF, Leach, MO, Liney, GP, Moss, SM, Padhani, AR, Parker, GJM, Pointon, LJ, Ponder, BAJ, Redpath, TW, Sloane, JP, Turnbull, LW, Walker, LG, Warren, RML & UK MRI Breast Screening Study Advisory Group 2000, 'Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study', Magnetic Resonance Imaging, vol. 18, pp. 765-776.
Brown, J ; Buckley, D ; Coulthard, A ; Dixon, A K ; Dixon, J M ; Easton, D F ; Eeles, R A ; Evans, D G R ; Gilbert, F G ; Graves, M ; Hayes, C ; Jenkins, J P R ; Jones, A P ; Keevil, S F ; Leach, M O ; Liney, G P ; Moss, S M ; Padhani, A R ; Parker, G J M ; Pointon, L J ; Ponder, B A J ; Redpath, T W ; Sloane, J P ; Turnbull, L W ; Walker, L G ; Warren, R M L ; UK MRI Breast Screening Study Advisory Group. / Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. In: Magnetic Resonance Imaging. 2000 ; Vol. 18. pp. 765-776.
@article{15c00566a581485ab4c38729e782d4de,
title = "Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study",
abstract = "The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.",
keywords = "breast cancer, genetic predisposition, screening, contrast agent, mammography, CONTRAST-ENHANCED MRI, GD-DTPA ENHANCEMENT, PHARMACOKINETIC ANALYSIS, PATHOLOGICAL CORRELATION, FAMILY HISTORY, LESIONS, DIAGNOSIS, DIFFERENTIATION, EXPERIENCE, CARCINOMA",
author = "J Brown and D Buckley and A Coulthard and Dixon, {A K} and Dixon, {J M} and Easton, {D F} and Eeles, {R A} and Evans, {D G R} and Gilbert, {F G} and M Graves and C Hayes and Jenkins, {J P R} and Jones, {A P} and Keevil, {S F} and Leach, {M O} and Liney, {G P} and Moss, {S M} and Padhani, {A R} and Parker, {G J M} and Pointon, {L J} and Ponder, {B A J} and Redpath, {T W} and Sloane, {J P} and Turnbull, {L W} and Walker, {L G} and Warren, {R M L} and {UK MRI Breast Screening Study Advisory Group}",
year = "2000",
language = "English",
volume = "18",
pages = "765--776",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study

AU - Brown, J

AU - Buckley, D

AU - Coulthard, A

AU - Dixon, A K

AU - Dixon, J M

AU - Easton, D F

AU - Eeles, R A

AU - Evans, D G R

AU - Gilbert, F G

AU - Graves, M

AU - Hayes, C

AU - Jenkins, J P R

AU - Jones, A P

AU - Keevil, S F

AU - Leach, M O

AU - Liney, G P

AU - Moss, S M

AU - Padhani, A R

AU - Parker, G J M

AU - Pointon, L J

AU - Ponder, B A J

AU - Redpath, T W

AU - Sloane, J P

AU - Turnbull, L W

AU - Walker, L G

AU - Warren, R M L

AU - UK MRI Breast Screening Study Advisory Group

PY - 2000

Y1 - 2000

N2 - The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.

AB - The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.

KW - breast cancer

KW - genetic predisposition

KW - screening

KW - contrast agent

KW - mammography

KW - CONTRAST-ENHANCED MRI

KW - GD-DTPA ENHANCEMENT

KW - PHARMACOKINETIC ANALYSIS

KW - PATHOLOGICAL CORRELATION

KW - FAMILY HISTORY

KW - LESIONS

KW - DIAGNOSIS

KW - DIFFERENTIATION

KW - EXPERIENCE

KW - CARCINOMA

M3 - Article

VL - 18

SP - 765

EP - 776

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

ER -